Question-and-Answer Session
Operator
Thank you. (Operator instructions) We will take our first question from Michael Yee of RBC Capital Markets.
Michael Yee – RBC Capital Markets
Great. Thanks. Congratulations on the products so far, David. Couple of questions. Just so we have our expectations in reality, what exactly – what type of data are we going to get at ASCO? Are we going to have the 60 milligram cohort followed out a number of months? Are we going to get the second and third cohorts reported out as well?
David Hung
Obviously, under the embargo rules of ASCO, we aren't allowed to disclose the details of the presentation and advancement of the meeting. We will be presenting more data. As we said, we've gone – dosed higher and more cohorts and at AACR, we only presented PSA data and the little imaging results that we saw in the FDG-PET and FDHT studies. So, we will be presenting more data but I'm really not at liberty to go into a lot more detail about what exactly that will be.
Michael Yee – RBC Capital Markets
Okay. On the Huntington's program, you've been saying you're going to complete in Q2. Do you think the actual release – the press release may fall into the third quarter's of what is possible?
David Hung
Yes, it is possible. We will release the results very shortly after we finish scrubbing all the data and going through the data analysis which will happen in the second quarter.
Michael Yee – RBC Capital Markets
But the release can actually fall in the third quarter?
David Hung
Yes.
Michael Yee – RBC Capital Markets
Okay and then last question, in terms of your 33% to 50% enrollment sites in the U.S. being – as you call that significant, do you have written or confirmed approval from the FDA that would fall under significant?
David Hung
I'll forward that question to Lynn.
Lynn Seely
As you know, the FDA will not decide that until the end of the study and they're actually looking at the data, but we do believe this represents the significant effort that they are looking for.
Michael Yee – RBC Capital Markets
Okay, great. Thanks guys.
Operator
Next we'll go to Ian Sanderson from Cowen and Company.
Ian Sanderson – Cowen and Co.
Yes. Thank you for taking the question. On the Alzheimer’s Phase III, have you disclosed the range of NMSC [ph] scores that are going to be use as enrollment criteria?
- To read the full transcript on Seeking Alpha, click here »
